Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca Sells 12,837 Shares

Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca sold 12,837 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $131.76, for a total value of $1,691,403.12. Following the completion of the transaction, the executive vice president directly owned 121,866 shares of the company’s stock, valued at $16,057,064.16. This trade represents a 9.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Merck & Co., Inc. Stock Up 2.1%

Shares of Merck & Co., Inc. stock opened at $133.10 on Thursday. The business’s fifty day moving average price is $124.94 and its two-hundred day moving average price is $119.64. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The company has a market capitalization of $328.38 billion, a P/E ratio of 106.48, a PEG ratio of 5.62 and a beta of 0.19. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $135.05.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Cascade Financial Partners LLC raised its stake in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after acquiring an additional 80 shares in the last quarter. Somerset Trust Co boosted its position in Merck & Co., Inc. by 0.9% during the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after purchasing an additional 81 shares during the period. Stonebridge Financial Group LLC grew its holdings in Merck & Co., Inc. by 0.9% during the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after purchasing an additional 81 shares during the last quarter. Stronghold Wealth Management L.L.C. grew its holdings in Merck & Co., Inc. by 2.6% during the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock valued at $416,000 after purchasing an additional 82 shares during the last quarter. Finally, Lederer & Associates Investment Counsel CA grew its holdings in Merck & Co., Inc. by 0.9% during the second quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company’s stock valued at $1,234,000 after purchasing an additional 84 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

MRK has been the topic of several research analyst reports. Barclays raised their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target for the company in a research note on Wednesday. Wells Fargo & Company increased their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Argus increased their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Fifteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $135.50.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst sentiment improved: Daiwa Securities upgraded Merck to “outperform” and set a $143 price target, while Argus raised its target to $145 and maintained a “buy” rating. These targets imply additional upside from recent trading levels. Daiwa Securities upgrade
• Positive Sentiment: RSV expansion opportunity: The FDA and European Medicines Agency accepted supplemental applications for broader use of ENFLONSIA to prevent RSV in vulnerable young children. The regulatory reviews could expand Merck’s growth beyond oncology and help diversify the portfolio ahead of Keytruda’s future patent expirations. Merck RSV regulatory review article
• Positive Sentiment: Estimates edged higher: Erste Group raised its FY2026 earnings forecast for Merck to $2.75 per share from $2.70, broadly aligning with the $2.76 consensus estimate. The company also recently exceeded quarterly revenue and adjusted earnings expectations, reporting $16.61 billion in revenue.
• Positive Sentiment: Core business remains solid: Keytruda, oncology and animal health supported quarterly growth, while the company continues investing in its pipeline. Merck also declared its regular $0.85 quarterly dividend, equivalent to a $3.40 annualized payout.
• Neutral Sentiment: Vaccine-policy uncertainty: Reports that the administration may seek to split the MMR vaccine into separate shots could create headlines around the broader vaccine market, but experts say the proposal lacks scientific support and is unlikely to advance. MMR vaccine policy article
• Negative Sentiment: Repeated insider selling: EVP Richard R. Deluca sold roughly 45,000 shares across transactions from August 6 through August 12 for approximately $6.7 million. Although he retained a substantial position, the sales may weigh modestly on sentiment.
• Negative Sentiment: Longer-term risks persist: Analysts continue to flag falling estimates, a high valuation and upcoming patent expirations, particularly the eventual loss of Keytruda exclusivity. These issues could limit upside unless Merck’s pipeline and newer products offset the expected revenue pressure.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.